RxDoctor Payments Data

Christopher Thacker, MD

Urology · Cleveland, TNNPI 1881658664

Payments from drug & device makers

$2,828in general payments, 2019–2025

Across 77 payments — averaging $36.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$1K
  • Johnson & Johnson$272
  • Sumitomo Pharma America, Inc.$195
  • Teleflex LLC$192
  • Dendreon Pharmaceuticals LLC$161
  • Boston Scientific$131
  • plus $796 from 19 others

What the payments were for

  • Travel & lodging$97234%
  • Food & beverage$1,81564%
  • Education$411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,828 in reported general payments places this provider in the 45th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$275,588
Medicare patients
621
Services billed
6,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix164$424,655
MyrbetriqMirabegron66$53,060
GemtesaVibegron30$26,821
Finasteride620$8,702
Tamsulosin Hcl544$8,121
Trospium Chloride ErTrospium Chloride29$6,273
Trospium Chloride52$5,963
Potassium Citrate ErPotassium Citrate38$4,427
Solifenacin Succinate64$3,676
Estradiol34$2,190
Alfuzosin Hcl ErAlfuzosin Hcl65$1,284
NitrofurantoinNitrofurantoin Macrocrystal28$1,177
Testosterone Cypionate20$893
Tolterodine Tartrate ErTolterodine Tartrate12$778
Oxybutynin Chloride ErOxybutynin Chloride15$695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$195$451,476194 claims
Astellas Pharma US IncMyrbetriq$81$53,06066 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 276 urology providers in Tennessee.

Other urology in Cleveland

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →